BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24677207)

  • 1. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.
    Edahiro Y; Morishita S; Takahashi K; Hironaka Y; Yahata Y; Sunami Y; Shirane S; Tsutsui M; Noguchi M; Koike M; Imai K; Kirito K; Noda N; Sekiguchi Y; Tsuneda S; Ohsaka A; Araki M; Komatsu N
    Int J Hematol; 2014; 99(5):625-34. PubMed ID: 24677207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms.
    Hu L; Pu L; Ding Y; Li M; Cabanero M; Xie J; Zhou D; Yang D; Zhang C; Wang H; Zhai Z; Ru X; Li J; Xiong S
    Hematology; 2017 Jul; 22(6):354-360. PubMed ID: 27976991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Impact of
    Yönal-Hindilerden İ; Şahin E; Hindilerden F; Dağlar-Aday A; Nalçacı M
    Turk J Haematol; 2023 Aug; 40(3):174-182. PubMed ID: 37584526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Combination of
    Wu S; Luo P; Rouzi T; Yu Y; Xiong B; Wang Y; Zuo X
    Cancer Control; 2023; 30():10732748231163648. PubMed ID: 36895113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
    Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
    Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
    Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.
    Perricone M; Polverelli N; Martinelli G; Catani L; Ottaviani E; Zuffa E; Franchini E; Dizdari A; Forte D; Sabattini E; Cavo M; Vianelli N; Palandri F
    Oncotarget; 2017 Jun; 8(23):37239-37249. PubMed ID: 28422729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
    Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
    Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
    Chen P; Ouyang J; Liang J; Yu X; Huang B
    Clin Lab; 2016 Aug; 62(8):1477-1481. PubMed ID: 28164603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].
    Kerguelén Fuentes AE; Hernández-Maraver D; Lombardia L; Canales Albendea MA; Rodriguez de la Rúa A
    Med Clin (Barc); 2012 Oct; 139(9):373-8. PubMed ID: 22743278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms.
    Fantasia F; Di Capua EN; Cenfra N; Pessina G; Mecarocci S; Rago A; Cotroneo E; Busanello A; Equitani F; Lo-Coco F; Nervi C; Cimino G
    Ann Hematol; 2014 Apr; 93(4):609-16. PubMed ID: 24173087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
    Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
    Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.
    Ayad MW; Nafea D
    Genet Test Mol Biomarkers; 2011; 15(1-2):17-21. PubMed ID: 21034166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
    Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A novel quantitative JAK2V617F detection kit: prospective clinical performance study comparing MPN patients and healthy subjects].
    Kirito K; Koike M; Noguchi M; Kizaki M; Katayama N; Sugimoto Y; Dobashi N; Usui N; Komatsu N
    Rinsho Ketsueki; 2018; 59(6):669-674. PubMed ID: 29973441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
    Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.